oper deliv standard
report first neg organ quarter sinc includ impact
defens project delay aero/defens -lsd soft
engin solut msd europ notabl soft na posit defens delay
repres time lsd es outlook expect flat organ order
normal december/januari divers includ substanti medic
subsystem compon oem report om expand bp
bp core note strong product tool playbook readi
flex softer organ period notic plu solid consist price
afford strong om visibl metal repres sale post-ra
divestitur vs ahead downturn mid/down
adjust ep beat
consensu guidanc sale core
acq fx vs estim op rose vs estim
guidanc ep establish vs prior estimate/
consensu y-o-i lsd sale growth flattish organ
sale grew y-o-i flat core acq om expand bp
bp organ vs estim emg sale fell
core fx om expand bp vs estim
order rose organ emg similarli
announc acquisit intellipow sale note
current avail cash/credit post transact strong pipelin
compani end net leverag gross cash
deploy te past two year similar year close acquisit
combin sale
consid flex capac leverag short term
dividend net proce read alloy sale expect close
quarter see financi capac next month frequenc
deal-siz opportun acceler estim read disposit
afford bp om accret emg dilut guidanc
maintain pt remain target
roughli consist current multipl support
sustain compound model factor highli probabl
increment acquir prospect solid return interim
year price histori
analyst certif import disclosur see disclosur
expect posit investor sentiment given
sustain compound model highli probabl
acquir prospect solid return high /ni convers
strong backlog underwrit outlook attent focus
solid order trend deal flow remain solid robust
recent deal play well oper improv capac
strong convers capit alloc prospect
acceler replenish record backlog
success mitig uncertain tariff headwind
inabl execut difficult organ comp
inabl execut integr acquisit expect
pt base roughli consist current multipl support sustain compound
model factor highli probabl increment acquir prospect solid return interim pt impli potenti
upsid includ dividend yield
risk includ weaker global growth includ us weak aerospac oil/gas/chem market inabl
complete/integr acquisit given relianc acquisit supplement top line inabl pass along higher raw materi cost
price aggress consensu ep estim time could hinder stock price perform
exhibit segment result varianc oppenheim estim
report adjust ep vs year ago beat estimate/
consensu guidanc revenu increas organ
acquisit fx vs estim order y-o-i core
emg low-singl digit similar
segment om expand bp y-o-i vs estim consolid basi
oper margin bp core bp vs estim
flow/liquid end net debt/ebitda gross cash hand
current avail cash/credit follow acquisit intellipow
guidanc manag establish ep guidanc vs prior estim
consensu y-o-i sale outlook low-singl digit organ sale flat
expect full-year tax rate capital-expenditure flat y-o-i depreci amort
guid ep vs prior line estim sale
low-singl digit
electron instrument revenu increas y-o-i flat organ acquisit vs
estim aerospac grew low-singl digit lsd organ process increas high-singl
digit flat organ power industri low-singl digit om expand bp core
bp vs estim
electromechan revenu fell y-o-i organ fx vs estim
engin solut organ sale decreas mid-singl digit oper margin
expand bp core bp beat estim
annual sale profit segment
compani report oppenheim co inc
quarterli sale profit segment
compani report oppenheim co inc
analysi oper
segment revenu
total segment revenu
segment profit
total segment profit
compani report oppenheim co inc
year end decemb million
good sold
oper profit g/w charg
compani report oppenheim co inc
sale
oper profit g/w charg
compani report oppenheim co inc
year end decemb million
equival
intang invest asset
short-term borrow current portion ltd
average day inventori day hand
compani report oppenheim co inc
consolid statement flow
year end decemb million
inventori current asset
payabl accrual incom tax
net chang work capit
addit pp
proce sale asset discontinu op
purchas busi net cash
net chang short-term borrow
reduct long-term borrow
repurchas common stock
excess tax benefit share-bas payment
proce employe stock option
increas dec
equival -b
equival -e
compani report oppenheim co inc
